Anidulafungin in Treating Immunocompromised Children With Neutropenia
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Anidulafungin may be effective in preventing fungal infections in
immunocompromised children who have neutropenia.
PURPOSE: This phase I/II trial is studying the side effects of anidulafungin and to see how
well it works in preventing fungal infections in immunocompromised children with neutropenia
caused by chemotherapy or aplastic anemia.